We value your privacy
We use cookies to improve your experience and analyze traffic. By continuing, you consent to our use of cookies under GDPR, CCPA and other applicable laws. Privacy Policy
Cookie preferences
Choose which categories of cookies you allow. Strictly necessary cookies are always on.
Strictly necessary
Required for core site functionality, security and your session. Always active.
Analytics
Help us understand how visitors use the site (e.g. Google Analytics) so we can improve it.
Marketing
Used to measure campaigns and show you relevant ads on other sites (e.g. LinkedIn, Google Ads).
The global Pneumococcal Vaccines Market size will be USD 8261.9 million in 2025.
Growing incidence of antimicrobial resistance (AMR) encouraging vaccination, which is expected to boost sales to USD 14195.48 million by 2033, with a Compound Annual Growth Rate (CAGR) of 7.00% from 2025 to 2033. Download a free sample with data verified by Supriya Yadav
How are Segments Performing in the Global Pneumococcal Vaccines Market?
Pneumococcal Vaccines Market Product Type Segment Analysis
According to Cognitive Market Research, Prevenar-13 is likely to dominate the Pneumococcal Vaccines Market. Because of its comprehensive protection against 13 serotypes of Streptococcus pneumoniae, Pfizer's Prevenar 13 vaccine is in high demand in the pneumococcal vaccines market. National vaccination programs, private healthcare facilities, and high-risk populations like newborns, the elderly, and patients with impaired immune systems all make extensive use of it. Government recommendations, increased disease prevalence, and growing adult immunization programs are the main drivers of demand. Its expanding use is further aided by hospital-based immunization programs, reimbursement regulations, and raised awareness. High demand is seen in developed regions like North America and Europe, while better access to healthcare is driving development in emerging markets.
Synflorix is the fastest-growing segment in the Pneumococcal Vaccines Market. Because it is affordable and included in national immunization programs, Synflorix, a product of GlaxoSmithKline (GSK), is in high demand in the pneumococcal vaccines market, especially in low- and middle-income nations. It is commonly used for pediatric vaccination and offers protection against ten serotypes of Streptococcus pneumoniae. Demand is driven by government-funded immunization programs, assistance from UNICEF, WHO, and Gavi, as well as rising awareness. Africa, Latin America, and Asia Pacific's emerging markets are important locations for expansion. Additionally, its commercial presence is strengthened, particularly in public healthcare systems, by its involvement in lowering incidences of otitis media and childhood pneumonia.
Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.
To learn more about market share and segmentation, request the free sample pages.
Competitor Analysis
Competitive Landscape of the Pneumococcal Vaccines Market
The market for pneumococcal vaccines is extremely competitive, with major manufacturers concentrating on research and development, the introduction of new products, and international growth. Prominent corporations include GlaxoSmithKline (Synflorix), Merck & Co., Inc. (Pneumovax, Vaxneuvance), and Pfizer Inc. (Prevnar series). Government partnerships and new biotech companies further heighten competition. To bolster their position in the burgeoning pneumococcal vaccination industry, businesses are investing in next-generation vaccines, reaching a wider audience, and forming strategic alliances.
Vaxcyte completed the phase-2 clinical study in March 2024 to assess the effectiveness of the 24-valent pneumococcal conjugate vaccine (PCV) candidate VAX-24 in eradicating invasive pneumococcal disease (IPD) in children. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-completes-enrollment-phase-2-study-evaluating-vax-24> In January 2024, The Committee of Medicinal Products Intended for Human Use (CHMP) of the European Medicines Agency (EMA) granted Pfizer Inc. marketing authorization for their 20-valent pneumococcal conjugate vaccine candidate (20vPnC). https://www.pfizer.com/news/announcements/pfizer-receives-positive-chmp-opinion-its-20-valent-pneumococcal-conjugate In October 2023, Lonza and Vaxcyte, Inc. worked together to sign a new commercial manufacturing contract. Vaxcyte intends to increase its commercial manufacturing capability for its PCV candidates with this partnership. https://www.lonza.com/news/2023-10-16-14-00 In April 2023, The FDA approved Pfizer Inc.'s Prevnar 20 to prevent newborns from contracting Invasive Pneumococcal Disease (IPD). https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal
Click any bar or cell to request the full company profile
Top Companies (In no particular order)
2022 (A)
2023 (A)
2024 (A)
2025 (A)
Serum Institute of India Pvt. Ltd.
•••
•••
•••
•••
CSL
•••
•••
•••
•••
Sanofi
•••
•••
•••
•••
GSK plc
•••
•••
•••
•••
Merck & Co. Inc.
•••
•••
•••
•••
Pfizer Inc.
•••
•••
•••
•••
Walvax Biotechnology Co. Ltd
•••
•••
•••
•••
Beijing Minhai Biotechnology Co. Ltd.
•••
•••
•••
•••
We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.
According to Cognitive Market Research, the global Pneumococcal Vaccines Market size will be USD 8261.9 million in 2025. It will expand at a compound annual growth rate (CAGR) of 7.00% from 2025 to 2033.
North America held the major market share for more than 40% of the global revenue with a market size of USD 3056.90 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 2395.95 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 1982.86 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 313.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
The Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 330.48 million in 2025. and will grow at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 181.76 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2033.
Synflorix category is the fastest growing segment of the Pneumococcal Vaccines Market
Introduction of the Pneumococcal Vaccines Market
The market for pneumococcal vaccinations is centred on those that are intended to guard against infections brought on by Streptococcus pneumoniae, a bacterium that causes meningitis, pneumonia, and septicemia. Particularly in newborns, older people, and immunocompromised people, these vaccinations, such as pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs), help lower morbidity and mortality. Growing immunization programs, increasing disease prevalence, and developments in next-generation vaccines are the main factors driving market dynamics. However, market expansion is constrained by high vaccine costs, restricted availability in low-income areas, and vaccine reluctance. Global market expansion prospects are presented by growing adult immunization programs, new product advancements, and more government assistance.
In April 2024, Merck announced the findings of the STRIDE-10 phase 3 clinical study, which developed an adult 21-valent pneumococcal conjugate vaccination. https://www.merck.com/news/merck-announces-positive-data-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults/
Analyst Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Pneumococcal Vaccine Market Analysis is witnessing significant growth in the near future.
In 2023, the Synflorix
segment accounted for a notable share of the Pneumococcal Vaccine Market Analysis.
Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.
Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.
In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.
Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.
The global market size for Pneumococcal Vaccines in 2025 is USD 8261.9 million.
The global Pneumococcal Vaccines Market is expected to grow with a CAGR of 7.00% over the projected period.
North America held a significant global Pneumococcal Vaccines Market revenue share in 2025.
Asia-Pacific will witness the fastest growth of the global Pneumococcal Vaccines Market over the coming years.
The US had the most significant global Pneumococcal Vaccines Market revenue share in 2025.
The main driver of the growth of the Pneumococcal Vaccines Market is the higher demand for immunization in war-torn and refugee-affected regions and the Increased use of AI and big data in vaccine distribution and monitoring.
The Public Authorities category dominates the market.
★ Reviews
Rate this report
Pneumococcal Vaccine Market Analysis — Table of Contents
Disclaimer:
This is just a redacted sample pages of the actual deliverable report and only for representative purposes
Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
If applicable; On Request Volume Data will also be provided (at an Additional Cost).
12.14.2 AI-Driven Transformation of Industry Value Chain
12.14.3 Evolution of Business Models & Revenue Streams
12.14.4 AI-Driven Product, Service & Innovation Transformation
12.14.5 Customer Behavior, AI Adoption & Future Market Evolution
Chapter 13. TOP 10 Country Analysis
13.1 Country 1
13.2 Country 2
13.3 Country 3
13.4 Country 4
13.5 Country 5
13.6 Country 6
13.7 Country 7
13.8 Country 8
13.9 Country 9
13.10 Country 10
Chapter 14. Research Findings
14.1 Key Takeaways
14.2 Analyst Point of View
14.3 Assumptions and Acronyms
Chapter 15. Research Methodology and Sources
15.1 Primary Data Collection
15.1.1 Steps for Primary Data Collection
15.1.1.1 Identification of KOL
15.1.2 Backward Integration
15.1.3 Forward Integration
15.1.4 How Primary Research Help Us
15.1.5 Modes of Primary Research
15.2 Secondary Research
15.2.1 How Secondary Research Help Us
15.2.2 Sources of Secondary Research
15.3 Data Validation
15.3.1 Data Triangulation
15.4 Data Representation
Athenaeum AI Dashboard
Research Framework · 70:30 Primary:Secondary
Our Proprietary Methodology
Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Pneumococcal Vaccine Market Analysis Market analysis.
01
Primary Intelligence Gathering
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
02
Secondary Data Triangulation
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
03
Expert Validation Protocol
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
04
Athenaeum AI Processing
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
05
Editorial & QA Review
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
Latest News about Pneumococcal Vaccine Market
24 Jun 2024health.economictimes.indiatimes.com
US FDA approves Merck's pneumococcal vaccine for adults
According to Merck, the FDA in the US has authorized its next-generation vaccine to guard against pneumococcal illness in adults. Pneumonia can result from infections caused by the illness in the lungs, among other sections of the body. The bacterium that may cause such diseases comes in around a hundred different types. In a range of adult populations across trials, Merck's vaccine, marketed under the trade name Capvaxive, assisted in eliciting an immune response against all 21 serotypes, or varieties of the bacterium, that the injection targeted. The vaccine costs USD 287 a dose at wholesale, according to the drugmaker, but most people will probably be able to get it for free if the advisors at the Centres for Disease Control and Prevention routinely suggest it. Currently, Merck offers two authorized pneumococcal vaccinations: Pneumovax 23 for people 50 years of age and above, as well as Vaxneuvance for those six weeks of age and older who are at an increased risk of contracting the illness.
The Three Pillars of End-to-End Market Research Services
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Pneumococcal Vaccine Market Analysis market.
Service 01
Market Survey
B2BB2C
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the pneumococcal vaccine market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
What's Included
Buyer intent & sentiment analysis
Purchase cycle mapping
Price sensitivity research
Channel preference profiling
Competitive perception study
Most Requested
Service 02
Customized Market Data & Reports
CustomReady Report
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
What's Included
Ready syndicate report
Custom data scope & segmentation
Excel quantitative models
Board-ready PPT with key findings
Secure cloud portal access
Service 03
Strategic Consultation
With SurveyWith Report
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.
Why Trust Us
What these certifications mean to usA market figure is only as reliable as the system that produced it. That is why our accreditations cover the whole chain, not just the research step. ESOMAR and MRSI membership binds us to the professional codes that govern how respondents are recruited and how findings may be represented. ISO 20252 governs the research process itself; ISO 9001 and our quality control certification govern how consistently we repeat it. ISO 27001 and ISO 27701, alongside our GDPR, CCPA and DPDP compliance, govern what happens to your brief and your data once it reaches us; because a confidential scope is often more sensitive than the deliverable. ISO 14001, our D-U-N-S registration, Chamber of Commerce membership and DMCA protection speak to how the company itself is run and how its work is safeguarded.Our Clutch and Trustpilot profiles are deliberately listed next to them. They are the only signals on this page we do not issue ourselves, and they are the ones we would check first if we were you.
I enjoyed reviewing all the contents of the report. I am wondering if you can generate similar reports for Orlistat and Mounjaro as you have provided for o…
